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A concise synthesis of 2’-deoxyisoguanosine is achieved whereby 2,6-dichloropurine is glycosylated using the 
Hoffer sugar to give a pair of beta-configured nucleoside N9/N7 regioisomers that are aminated using 
methanolic ammonia with concomitant deprotection of the sugar. Following chromatographic separation, 
pure 2-chloro-2’-deoxyadenosine was isolated as a single isomer. Displacement of the C2 chlorine atom using 
sodium benzyloxide, followed by hydrogenolysis of the benzyl group, gives 2’-deoxyisoguanosine. Isoguanine 
was incorporated into DNA by solid supported synthesis using the suitably protected 2-allyloxy-2’-
deoxyadenosine phosphoramidite with the allyl group being removed post-oligomerisation under Noyori 
conditions. DNA melting studies showed isoguanine to exhibit adenine-like triplex formation. 
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Introduction 
 
Although not a DNA base, isoguanine (isoG) occurs naturally and various methods have been reported for the 
preparation of derivatives1-4 including its riboside,5 2’-deoxyriboside6-9 and other analogues.10,11 Isoguanine 
has been widely studied and when incorporated into nucleic acids,12-23 has been shown to form stable base 
pair7,24-28 (Figure 1 left) and triplex motifs29 (Figure 1 middle) as its N3-H tautomer. These experimental 
observations are supported by theoretical calculations.7,30,31 Strong, Watson-Crick purine-purine base pairing 
is one of various defining features of 2’,3’-dideoxyhexose nucleic acid duplexes whereby isoguanine adopts 
the N1-H tautomeric form32 (Figure 1 right). In pyranosyl-RNA duplexes, isoguanine adopts either N3-H or N1-
H tautomeric forms.33 
 
Figure 1. Representative motifs in oligonucleotides where the N3-H tautomer of isoguanine (isoG) is targeted 
to isocytosine7 (isoC), to a guanine.cytosine (G.C) base pair29 and as the N1-H tautomer, targeted to guanine32 
(G). 
 
 We sought to examine whether isoguanine could exhibit adenine (A)-like triplex formation in its N1-H 
tautomeric form when incorporated into DNA, thus extending the triplex-froming capabilities of this particular 
purine heterocycle (Figure 2 right). To accompany the incorporation of isoguanine into DNA, we considered 2-
benzyloxyadenine (B) and 2-allyloxyadenine (L) as further representations of the adenine hydrogen bonding 
pattern for additional, viable triplex formation (Figure 2 left). At the nucleoside level, hydrogenolysis of the 2-
benzyloxy group34 would give a concise route to 2’-deoxyisoguanosine from non-nucleoside precursors. At the 
DNA level, removal of the 2-allyloxy group using Noyori conditions35 would give isoguanine29 (Figure 2 right) 
for the study of its triplex-forming properties and also allow comparison between A, isoG, B and L. 
 
 
Figure 2. Triplex DNA motifs involving adenine (A) and the adenine-like 2-benzyloxyadenine (B), 2-
allyloxyadenine (L) (left) and N1-H tautomer of isoguanine (isoG) (right). 
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Results and Discussion 
 
As the starting point for synthesis of the nucleoside intermediate 5,36 we selected the well-known and widely 
used6,29,37-41 Hoffer sugar 2 (2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride).42 Recently, we 
reported an improved synthesis of the Hoffer sugar that was achieved without need for distillation or 
chromatographic separation of intermediates, or the use of gaseous HCl.43 The sodium salt of 2,6-
dichloropurine (1) was generated, in situ, using NaH in MeCN.41 Addition of Hoffer’s sugar 243 to the reaction 
mixture afforded the nucleoside regioisomers 3 (N9) and 4 (N7), as a 4:1 mixture (Scheme 1). 
Chromatographic separation of the regioisomers 3 and 4 was possible41,44 but in our hands it proved to be 
tricky and time consuming. Thus the mixture of regioisomers 3 and 4 was treated with methanolic ammonia 
solution (6 h) with heating (100 °C) to afford 2-chloro-2’-deoxyadenosine isomers 5 and 6 that were readily 
separated by flash chromatography (Scheme 1).  
 The preparation of 2-benzyloxy-2’-deoxyadenosine (7) was achieved by adding nucleoside 5 to solution of 
benzylalkoxide that was generated by mixing sodium hydride (50% dispersion in paraffin oil) and benzyl 
alcohol with heating (80 °C). Continued heating for 12 h at 85 °C afforded 2-benzyloxy-2’-deoxyadenosine (7) 
following chromatographic purification (71%) (Scheme 2). The benzyl group was removed from nucleoside 7 
by catalytic hydrogenolysis (6.5 h) to give 2'-deoxyisoguanosine (9) in 53% yield thus providing a concise, four-
step route to 9 from non-nucleoside precursors. The analytical and spectroscopic properties were in 
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Scheme 2. Reagents and conditions: i, sodium benzylalkoxide, 85 °C, 12 h; ii, sodium allylalkoxide, 88 °C, 12 h; 
iii, H2, Pd-C, MeOH, rt, 6.5 h. 
 
 2-Allyloxy-2’-deoxyadenosine (8) was prepared in a similar fashion to the 2-benzyloxy derivative 7 using 
allyl alcohol (Scheme 2). Separately, the amino groups in nucleosides 7 and 8 were protected by reaction with                       
N,N-dimethylacetamide dimethyl acetal in anhydrous methanol (Scheme 3). The volatile reagents were 
removed under vacuum and the crude products 10 and 12 used in the next step without further purification. 
Separately, the 5'-hydroxyl functions of 10 and 12 were protected using 4,4’-dimethoxytrityl chloride affording 
11 (88%) and 13 (68%) over 2 steps. Phosphitylation at the 3’-hydroxyl functions of 11 and 13 using 2-
cyanoethyl-N,N-diisopropyl chlorophosphoramidite afforded the DNA monomers 14 and 15 as mixtures of 
diastereoisomers. Following initial chromatographic purification, the phosphoramidites 14 and 15 were 
precipiated, separately, into hexane to remove residual non-phosphoramidite impurity from compound 14 





Scheme 3. Reagents and conditions: i, N,N-dimethylacetamide dimethyl acetal, MeOH, 40 °C, 26 h; ii, DMTCl, 
pyridine, rt, 12 h or 110 min ; iii, 2-cyanoethyl-N,N-diisopropyl chlorophosphoramidite, THF, rt, 40 min or 1 h. 
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 The DNA sequences S1 to S7 were prepared by solid supported synthesis on a 1 μmol scale using 
phosphoramidites including 14 to insert the 2-benzyloxyadenine (B) into S6, and 15 to insert 2-allyloxyadenine 
(L) and isoguanine (I) into S4 and S5. Cleavage and deprotection (16 h) using conc. NH3 (aq) at 55 °C afforded 
the crude oilgomers that were purified by reversed phase HPLC and analysed by negative ion electrospray 
mass spectrometry in weakly basic ammonia solution (Table 1). 
 
Table 1. HPLC retention times and the found and calculated masses of prepared DNA sequences S1 to S7. 
 
Entry Sequencea tR/minc Mass Foundd Mass Calculated 
S1 3'-d(TTTTCTTTTCCCCCCT) 13.8 4698.8 4697.8 
S2 5'-d(AAAAGAAAAGGGGGGA) 12.6 5061.4 5058.9 
S3 3'-d(AAAAGAAAAGGGGGGA) 12.4 5060.7 5058.9 
S4 3'-d(AAAAGAAIAGGGGGGA)b 12.7 5076.9 5074.9 
S5 3'-d(AAAAGAALAGGGGGGA) 12.6 5119.7 5115.0 
S6 3'-d(AAAAGAABAGGGGGGA) 14.2 5168.0 5165.0 
S7 3'-d(AAAAGAAGAGGGGGGA) 12.7 5075.8 5074.9 
 
a A = adenine, I = isoguanine, L = 2-benzyloxyadenine, B = 2-allyloxyadenine, G = guanine. b Removal of the 2-
O-allyl protecting group to give I was achieved post-oligomerisation using Noyori conditions.35 c Gradient 
elution 260 nm) using a C18 Reversed Phase Column (250 x 4.6 mm) at a flow rate of 1 mL.min-1 where solvent 
system A was mixed with solvent system B. Solvent system A was composed of 1 M aqueous 
triethylammonium acetate (TEAA, 10%) and MeCN (2%) at pH 7.0, and solvent system B was composed of 1 M 
aqueous TEAA (10%) and MeCN (80%) at pH 7.0. d The molecular masses and masses of mono-sodium adducts 
(not shown) were measured from the deconvoluted mass-to-charge (m/z) ratios of the multiply-charged 
anions from electrospray mass spectrometry and were consistently within ±0.08% of their calculated values. 
 
 The thermal denaturation of the triple helices formed from sequences S3 to S7 targeted to duplex S2.S1 
is summarised in Table 2. In each case the S2.S1 duplex melting temperature remained unchanged regardless 
of the sequence of the third strand S3 to S7. Notable was the sensitivity of the triplex to mismatch where the 
presence of X = G in sequence S7 was significantly destabilising to the triplex structure. 
 Triplexes formed from S3 (X = A) and S4 (X = I) targeted to S2.S1 were identical in stability demonstrating 
adenine-like triplex formation (Figure 1 left) by isoguanine, with the likelihood of isoguanine adopting the N1-
H tautomer (Figure 1 right). The 2-benzyloxy (B) and 2-allyloxy (L) derivatives of adenine were accommodated 
in triplex structures S5*S2.S1 and S6*S2.S1 without loss of stability, again supporting the adenine-like triplex 
formation (Figure 2 left). Spermine is known to stabilise DNA triplexes and its addition was equally stabilising 
to both the adenine- and isoguanine-containing triplexes S3*S2.S1 and S4*S2.S1 (Table 2). 
 To examine the preferred or dominant modes of tautomerization, we performed semi-empirical (AM1) 
calculations on tautomers of N9-methylisoguanine as representative structures. The similarity between the 
calculated heats of formation around 53 kcal.mol-1 suggested that isoguanine exists in more than one stable 
tautomer including the N1-H form ascribed to its adenine-like triplex forming behaviour (Figure 2 right) and to 
its characteristic duplex-forming behaviour in 2’,3’-dideoxyhexose-DNA32 (Figure 1, right). 
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Table 2. The thermal stability of triplexes containing X = A compared with X = I, L, B and G. 
 
    3’-dTTTTCTTTTCCCCCCT-5’ S1 
    5’-dAAAAGAAAAGGGGGGA-3’ S2 
    3’-dAAAAGAAXAGGGGGGA-5’ S3-S7 
 
Triplex TFOs  (S3-S7)a Tm/°Cb Tm/°Cc 
S3*S2.S1  X = A 15 ±1 59.0 ±0.5 
S4*S2.S1  X = I 15 ±1 59.0 ±0.5 
S3*S2.S1 X = A  23 ±1d  59.0 ±0.5 
S4*S2.S1 X = I  23 ±1d 59.0 ±0.5 
S5*S2.S1 X = L 16 ±1 59.0 ±0.5 
S6*S2.S1 X = B  15 ±1 59.0 ±0.5 
S7*S2.S1 X = G  < 5 59.0 ±0.5 
 
a A = adenine, I = isoguanine, L = 2-benzyloxyadenine, B = 2-allyloxyadenine, G = guanine. b Triplex S3 to 
S7*S1.S2 melting temperature. c Duplex S2.S1 melting temperature. d 0.5 mM spermine added. Denaturation 
was performed with 1.5 mM of each sequence in 0.1 M NaCl, 0.01 M MgCl2, 25 mM Tris.HCl buffer at pH 7.2 at 





Figure 3. The calculated (AM1) heats of formation ΔHf (kcal.mol-1) for N9 methylated isoguanine tautomers 16 




We have established a concise synthesis of isoguanine 2’-deoxyriboside from non-nucleoside starting 
materials 2,6-dichloropurine 1 and the Hoffer sugar 2. Isoguanine was incorporated into DNA and shown to 
participate in adenine-like triplex formation. Analogous behavior was observed for 2-benzyloxyadenine and 2-
allyloxyadenine.  
 The DNA melting studies and semi-empirical heats of formation calculated for representative N9-
methylated isoguanine tautomers, support the viability of isoguanine as its N1-H tautomer in DNA triplex 
formation thus furthering the elucidation of the molecular recognition characteristics of this particular purine 
heterocycle. 
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Experimental Section 
 
General. NMR spectra were recorded on a Bruker AC-250 spectrometer with 1H (250.1 MHz) spectra 
referenced to TMS, 13C spectra (62.9 MHz) referenced to CDCl3 or (CD3)2SO, and 31P spectra (101.3 MHz) 
referenced to 85% H3PO4 (aq). Mass spectrometric analysis were carried out at EPSRC (Swansea) in EI+ or CI+ 
mode using a VG Quatro II or FAB+ mode using a VG AutoSpec instrument or at Aston University in 
electrospray ionisation (ES) mode with a Hewlett-Packard HP 5989B MS Engine apparatus using a HP 59987A 
API-electrospray LC/MS interface. Electron impact ionisation (EI) mass spectra (70eV) were recorded on a AEI 
MS1Z mass spectrometer. Infrared spectra were recorded using a Mattson Galaxy 2020 FT-IR 
Spectrophotometer. Ultraviolet spectra were recorded using a Unicam PU8730 Spectrophotometer. Melting 
points were measured on a Gallenkamp Electrothermal Digital apparatus and are uncorrected. Flash column 
chromatography was performed using Sorbsil C60 silica using the method described by Still, Kahn and Mitra.45 
TLC was carried out on pre-coated Merck 60 F254 aluminium-backed plates and visualized using UV (254 and 
366 nm) and vanillin reagent; vanillin (6.0 g), ethanol (250 mL) and conc. sulfuric acid (2 mL). Oligonculeotides 
were prepared on a Beckman Oligo 1000 DNA synthesiser following the manufacturer’s protocol using 
commercially available reagents (LINK Technologies). Purification of oligonucleotides was performed by semi-
preparative reverded phase HPLC. Thermal UV analysis of oligonucleotides was conducted using a Varian Cary 
1E UV-Visible Spectrophotometer with a 12 sample heating block. 
6-Amino-2-chloro-9-(2'-deoxy-β-D-erythro-pentofuranosyl)-purine (5) and 6-amino-2-chloro-7-(2'-deoxy-β-D-
erythro-pentofuranosyl)-purine (6). A mixture of 2,6-dichloropurine (1) (5.00 g, 26.45 mmol) and sodium 
hydride (1.13 g, 28.25 mmol, 60% dispersion in oil) in anhydrous MeCN (100 mL) was stirred (90 min) at rt 
under Ar. Hoffer’s sugar43 2 (10.28 g, 26.46 mmol) was added in four equal portions during 30 min. After 24 h, 
the reaction mixture was filtered through Celite. Evaporation of the solvent gave a crude mixture of 
nucleosides 3 and 4 (7.82 g) in a 4:1 ratio by 1H NMR. A saturated solution of methanolic NH3 (70 mL) was 
added to a portion (3.02 g) of the crude mixture of nucleosides 3 and 4, and the mixture was heated (6 h) in a 
bomb at 100 °C. The product solution was evaporated concentrated. The residue was purified by flash 
chromatography, eluting with CH2Cl2-MeOH (9:1) to give N9 isomer 5 (0.40 g, 14% over 2 steps); mp >300 °C 
(lit.46 mp >300 °C); TLC [MeOH-CH2Cl2 (1:4)]: Rf 0.38; 1NMR [(CD3)2SO]:  2.20-2.30 (m, 1 H, 2'-CH2), 2.60-2.70 
(m, 1 H, 2'-CH2),  3.40-3.60 (m, 2 H, 5'-CH2), 4.38 (m, 1 H, 3'-CH), 4.99 (t, 1 H, J 5.8 Hz, 5'-OH), 5.34 (d, 1 H, J 4.2 
Hz, 3'-OH), 6.26 (t, 1H, J 6.4 Hz, 1'-CH), 7.86 (br s, 2 H, NH2), 8.34 ppm (s, 1 H, 8-CH). Further elution gave the 
N7 isomer 6 (0.10 g, 3% over 2 steps); mp >300 °C (lit.46 mp >300 °C); TLC [MeOH-CH2Cl2 (1:4)]: Rf 0.24; 1H 
NMR [(CD3)2SO]:  2.28-2.33 (m, 2 H, 2'-CH2), 3.42 (m, 2 H, 5'-CH2), 3.90 (m, 1 H, 4'-CH), 4.39 (m, 1 H, 3'-CH), 
5.19 (t, 1 H, J 4.6 Hz, 5'-OH), 5.41 (d, 1 H, J 4.5 Hz, 3'-OH), 6.30 (t, 1 H, 6.3 Hz, 1'-CH), 7.49 (br s, 2 H, NH2), 8.56 
ppm (s, 1 H, 8-CH); 13C NMR [(CD3)2SO]:  41.2 (2'-C), 60.4 (5'-C), 69.3 (3'-C), 85.7 (1'-C), 88.0 (4'-C), 109.6 (5-C), 
144.8 (8-C), 152.7 (6-C or 2-C), 153.2 (6-C or 2-C), 162.2 ppm (4-C). 
6-Amino-2-benzyloxy-9-(2'-deoxy-β-D-erythro-pentofuranosyl)-purine (7). Sodium as a 50% dispersion in 
paraffin oil (190 mg, 8.26 mmol) was added to anhydrous benzyl alcohol (15 mL) under Ar and the mixture was 
heated at 80 °C for 45 min to give a clear, colourless solution. The nucleoside 5 (450 mg, 1.58 mmol) was then 
added and the solution was heated at 85 °C during 12 h. Silica (10 g) and MeCN (15 mL) were then added to 
the cooled, deep-red, reaction mixture and the solvent evaported. The resulting gel was added to a column of 
silica gel and the unreacted benzyl alcohol was eluted firstly using CH2Cl2 and then CH2Cl2-MeOH (95:5). 
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Further elution with 10% MeOH-CH2Cl2 afforded the title compound 7 (400 mg, 71%) as a yellow solid; mp 
206-209 °C; TLC [MeOH-CH2Cl2 (1:4)]: Rf 0.52; IR (cm-1) 3396, 3132, 2937, 1653, 1592; 1H NMR [(CD3)2SO]:  
2.22 (m, 1 H, 2'-CH2), 2.71 (m, 1 H, 2'-CH2), 3.50-3.58 (m, 2 H, 5'-CH2), 3.85 (m, 1 H, 4’-CH), 4.41 (m, 1 H, 3’-CH), 
5.07 (t, 1 H, J 5.6 Hz, 5’-OH), 5.31-5.33 (m, 3 H, CH2 and 3’-OH), 6.26 (t, 1 H, J 6.4 Hz, 1’-CH), 7.31-7.47 (m, 7 H, 
5 x CH (Ar), NH2), 8.16 ppm (s, 1 H, 8-CH); 13C NMR [(CD3)2SO]:  39.2 (2’-CH2), 62.1 (5’-CH2), 67.9 (CH2), 71.2 
(3’-CH), 83.7 (1’-CH), 88.0 (4’-CH), 116.0 (5-C), 127.9 (CH (Ar)), 128.0 (CH (Ar)), 128.5 (CH (Ar)), 137.6 (C (Bn)), 
138.6 (8-CH), 150.8 (4-C), 157.0 (6-C) and 161.2 ppm (2-C). Mass spectrum (ES+): m/z (Ir) 358 (M + H, 100%), 
113 (35%); Calcd for C17H19N5O4: 410.008. Found 410.009; Calcd for C17H19N5O4: C, 57.1%; H, 5.3%; N, 19.6%. 
Found 57.2%; H, 5.3%; N, 19.5%. 
6-Amino-2-allyloxy-9-(2'-deoxy-β-D-erythro-pentofuranosyl)-purine (8). Sodium (640 mg, 27.83 mmol) as a 
50% dispersion in paraffin oil, was added to allyl alcohol (14 mL) in three portions during 5 min at 0 °C under 
Ar. After 1 h, the nucleoside 5 (0.76 g, 2.65 mmol) was added and the mixture was heated at 88 °C during 12 h 
after which time the mixture was concentrated to give a red oil which was purified by flash chromatography 
by gradient elution using CH2Cl2 containing MeOH (0 to 20%) to afford the title compound 8 (0.50 g, 62%) as a 
cream coloured solid.; mp 170-173 °C; TLC [MeOH-CH2Cl2 (1:4)]: Rf 0.47; IR (cm-1) 3371, 3336, 2942, 2874, 
1662, 1610; 1H NMR [(CD3)2SO]:  2.22 (m, 1 H, 2'-CH2), 2.71 (m, 1 H, 2'-CH2), 3.53 (m, 2 H, 5'-CH2), 3.84 (m, 1 
H, 4’-CH), 4.38 (m, 1 H, 3’-CH), 4.74 (m, 2 H, CH2O), 5.04 (br s, 1 H, 5’-OH), 5.17-5.38 (m, 3 H, CH2, 3’-OH), 6.03 
(m, 1 H, CH), 6.22 (t, 1 H J 6.9 Hz, 1’-CH), 7.32 (br s, 2 H, NH2), 8.13 ppm (s, 1 H, 8-CH); 13C NMR [(CD3)2SO]:  
40.0 (2’-C), 62.0 (5’-C), 66.8 (CH2O), 71.0 (3’-C), 83.5 (1’-C), 87.8 (4'-C), 115.7 (5-C), 116.9 (CH2), 134.0 (CH), 
138.4 (8-C), 150.7 (4-C), 156.9 (6-C), 160.9 ppm (2-C). Mass spectrum (ES+): m/z (Ir) 308 (M + H, 100%); Calcd 
for C13H17N5O4: (M + H) 308.136. Found 308.135; Calcd for C13H17N5O4: C, 51.0%; H, 5.2%, N, 22.9%. Found 
50.7%; H, 5.5%; N, 22.5%. 
2’-Deoxyisoguanosine (9). To nucleoside 7 (270 mg, 0.75 mmol) dissolved in MeOH (70 mL) was added 5% Pd 
on C (220 mg) and the mixture was hydrogenolysed (6.5 h) at rt using a hydrogen baloon. The product mixture 
was filtered through Celite after which activated charcoal (1 g) was added and the mixture was boiled for 10 
min. The charcoal was removed by filtration before concentration of the product mixture, affording the title 
compound 9 (110 mg, 53%) as an off-white solid; decomposed >230 °C (lit.8 decomposed >230 °C); 1H NMR 
[(CD3)2SO]:  2.14 (m, 1 H, 2'-CH2), 2.49 (m, 1 H, 2'-CH2), 3.53 (m, 2 H, 5'-CH2), 3.83 (m, 1 H, 4’-CH), 4.33 (m, 1 
H, 3’-CH), 5.27 (br s, 1 H, 3’-OH), 5.60 (br s, 1 H, 5’-OH), 6.09 (t, 1 H, J 7.9 Hz, 1’-CH), 7.70 (br s, 2 H, NH2), 7.94 
(s, 1 H, 8-CH), 10.70 ppm (br s, 1 H, NH); 13C NMR [(CD3)2SO]:  39.3 (2’-C), 62.0 (5’-C), 71.1 (3’-C), 83.8 (1’-C), 
88.0 (4’-C), 109.6 (5-C), 137.7 (8-C), 152.5 (6-C), 156.1 ppm (2-C). 
6-Amino-2-benzyloxy-6-N-[1-(dimethylamino)-ethylidene]-9-(2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-β-D-
erythro-pentofuranosyl)-purine (11). Nucleoside 7 (550 g, 1.54 mmmol) was coevaporated with anhydrous 
pyridine (3 x 10 mL), dissolved in anhydrous MeOH (3 mL) and placed under Ar. To this was added N,N-
dimethylacetamide dimethyl acetal (0.68 mL, 4.65 mmol) and the mixture was heated at 40 °C. After 26 h, H2O 
(0.3 mL) was added and the mixture stirred for a further 10 min. The mixture was concentrated, the residue 
co-evaporated with anhydrous pyridine (3 x 3 mL) and dissolved in pyridine (15 mL) under Ar. DMTCl (640 mg, 
1.89 mmol) was added and the solution stirred (12 h) after which time MeOH (0.5 mL) was added and stirring 
continuted (10 min). The mixture was concentrated and purified by flash chromatography eluting firstly with 
EtOAc-Et3N (100:1) and then MeOH-EtOAc-Et3N (5:95:1, then 10:90:1) affording a yellow foam. This was 
precipitated from CH2Cl2 (3 mL) into cold hexane-Et2O (2:1, 700 mL). The product was dissolved in CH2Cl2 (10 
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mL) and dried under high vacuum at 40 °C to give the title compound 11 (990 mg, 88% yield over 2 steps) as a 
white solid; mp 102-105 °C; TLC [MeOH-EtOAc-Et3N (10:90:1)]: Rf 0.37; IR (cm-1) 3413, 2929, 1606, 1564; 1H 
NMR [(CD3)2SO]:  2.01 (s, 3 H, CH3C), 2.27 (m, 1 H, 2’-CH2), 2.81 (m, 1 H, 2’-CH2), 3.08 (s, 8 H, 5’-CH2, (CH3)2N), 
3.68 (s, 6 H, 2 x CH3O), 3.96 (m, 1 H, 4’-CH), 4.45 (m, 1 H, 3’-CH), 5.17 (m, 2 H, CH2), 5.34 (m, 1 H, 3’-OH), 6.32 
(m, 1 H, 1’-CH), 6.68-7.35 (m, 18 H, 13 x CH (Ar), 5 x CH (Ar)), 8.13 ppm (s, 1 H, 8-CH); 13C NMR [(CD3)2SO]:  
17.2 (CH3C), 37.1, 38.2, ((CH3)2N), 38.4 (2’-CH2), 54.96, 54.99 (2 x CH3O), 64.5 (5'-CH2), 68.1 (CH2), 70.8 (3’-CH2), 
83.5 (1’-CH), 85.4 (Ar3C), 86.0 (4’-CH), 113.1 (CH), 122.3 (5-C), 126.6 (CH), 127.7 (CH (Ar)), 127.8 (CH (Ar)), 
128.3 (CH (Ar)), 129.65 (CH (Ar)), 129.72 (CH (Ar)), 135.5 (C), 135.7 (C), 137.3 (C (Ar)), 140.2 (8-CH), 145.0 (C 
(Ph)), 152.0 (4-C), 157.97 (COCH3), 158.01 (COCH3), 160.7, 160.9, 161.3 ppm (C-2, C-6, C=N); Mass spectrum 
(FAB+): m/z (Ir) 729 (M + H, 50%), 303 (100%); Calcd for C42H44N6O6: (M + H) 729.340. Found 729.343; Calcd for 
C42H44N6O6: C, 69.2%; H, 6.0%; N, 11.5%. Found C, 68.7%; H, 6.0%; N, 11.5%. 
6-Amino-2-allyloxy-6-N-[1-(dimethylamino)-ethylidene]-9-(2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-β-D-erythro-
pentofuranosyl)-purine (13). The nucleoside 8 (890 mg, 2.90 mmol) was co-evaporated with anhydrous 
pyridine (3 x 10 mL) and dissolved in anhydrous MeOH (2 mL) under Ar. To this, N,N-dimethylacetamide 
dimethylacetal (1.7 mL, 11.63 mmol) was added and the mixture stirred (47 h) at rt before water (0.3 mL) was 
added and stirring continued (10 min). The product mixture was concentrated, the residue co-evaporated with 
anhydrous pyridine (3 x 3 mL) and dissolved in pyridine (40 mL) under Ar. DMTCl (1.08 g, 3.19 mmol) was 
added in two portions during 20 min and the solution stirred (110 min) at rt after which MeOH (0.05 mL) was 
added and stirring continued (10 min). The product mixture was concentrated and the residue purified by 
flash chromatography, eluting with MeOH-EtOAc-Et3N (5:95:1 and then 10:90:1) affording a yellow foam 
which was precipitated from CH2Cl2 (3 mL) into hexane-Et2O (2:1, 750 mL). The product was dissolved in CH2Cl2 
(3 mL) and dried under high vacuum to give the title compound 13 (1.33 g, 68% yield over 2 steps) as a white 
solid; mp 98-101 °C; TLC [MeOH-EtOAc-Et3N (10:90:1)]: Rf 0.26; IR (cm-1) 3265, 2929, 1564, 1505; 1H NMR 
[(CD3)2SO]:  2.04 (s, 3 H, CCH3), 2.32 (m, 1 H, 2’-CH2), 2.87 (m, 1 H, 2’-CH2), 3.00-3.20 (m, 8 H, N(CH3)2 and 5’-
CH2), 3.69 (s, 3 H, CH3O), 3.70 (s, 3 H, CH3O), 3.98 (m, 1 H, 4’-CH), 4.49 (m, 1 H, 3’-CH), 4.69 (m, 2 H, CH2O), 
5.16-5.41 (m, 3 H, CH2 and 3’-OH), 6.00 (m, 1 H, CH), 6.73-7.34 (m, 13 H, 13 x CH (Ar)), 8.14 ppm (s, 1 H, 8-CH); 
13C NMR [(CD3)2SO]: d 17.4 (CH3C), 38.2, 38.4 (CH3)2N), 38.6 (2’-CH2), 55.1 (CH3O), 55.2 (CH3O), 64.6 (5’-CH2), 
67.2 (CH2), 71.0 (3’-CH), 83.5 (1’-CH), 85.6 (Ar3C), 86.0 (4’-CH), 113.2 (CH (Ar)), 113.2 (CH (Ar)), 117.1 (CH2), 
122.4 (5-C), 126.8 (CH (Ar)), 127.9 (CH (Ar)), 129.8 (CH (Ar)), 129.9 (CH (Ar)), 134.1 (CH), 135.7 (C), 135.8 (C), 
140.2 (8-CH), 145.1 (C (Ph)), 152.2 (C-4), 158.2 (2 x COCH3), 160.8, 161.1, 161.4 ppm (C2, C6, C=N); Mass 
spectrum (FAB+): m/z (Ir) 679 (M + H, 55%), 303 (100%); Calcd for C38H42N6O6: (M + H) 679.324. Found 679.326; 
Calcd for C38H42N6O6: C, 67.3%; H, 6.2%; N, 12.4%. Found C, 66.8%; H, 6.0%; N, 12.3%. 
6-Amino-2-benzyloxy-6-N-[1-(dimethylamino)-ethylidene]-9-(2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-D-erythro-
pentofuranosyl)-purine-3'-O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (14). Nucleoside 11 (200 mg, 
0.28 mmol) was dried by coevaporation with anhydrous pyridine (3 x 5 mL) and suspended in anhydrous THF 
(5 mL) under Ar. DIPEA (0.19 mL, 1.09 mmol) followed by 2-cyanoethyl-N,N-diisopropyl 
chlorophosphoramidite (0.09 mL, 0.40 mmol) were then added with stirring. After 40 min a white precipitate 
had formed and the product mixture was concentrated and the residue purified by flash chromatography 
eluting with EtOAc-CH2Cl2-Et3N (50:50:1) affording an oil which was precipitated five times from CH2Cl2 (3 mL) 
into cold hexane (300 mL). The product was dissolved in CH2Cl2 (3 mL) and dried under high vacuum at 30 °C 
giving the title compound 14 (0.09 g, 33%) as a colourless viscous oil; mp 66-69 °C; TLC [EtOAc-CH2Cl2-Et3N 
(50:50:1)]: Rf 0.28; IR (cm-1): 3551, 3473, 2962, 2961, 1606, 1570; 1H NMR [(CD3)2SO]:  0.95-1.23 (m, 12 H, 4 x 
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CH3), 2.03 (s, 3 H, CH3C), 2.62 (t, 1 H J 5.8 Hz, CH2CN), 2.74 (t, 1 H J 5.8 Hz, CH2CN), 2.95-3.25 (m, 8 H, (CH3)2N, 
2’-CH2), 3.40-3.80 (m, 12 H, 2 x CH3O, POCH2, 2 x NCH, 5’-CH2), 4.10 (m, 1 H, 4’-CH), 4.82 (m, 1 H, 3’-CH), 5.11-
5.24 (m, 2 H, CH2), 6.31 (m, 1 H, 1’-CH), 6.68-7.35 (m, 18 H, 13 x CH (Ar), 5 x CH (Ph)), 8.16, 8.17 ppm (2 s, 1 H, 
8-CH); 13C NMR [(CD3)2SO]:  17.2 (CH3C), 19.8 (CH2CN), 24.1, 24.2 (4 x CH3), 37.0, 37.1 (2’-CH2), 37.6, 38.1 
((CH3)2N), 42.5, 42.7 (2 x NCH), 54.9 (2 x CH3O (Ar)), 58.2, 58.3, 58.4, 58.6 (POCH2CH2CN), 63.8 (5’-CH2), 68.1, 
68.2 (CH2 (Ph)), 73.3, 73.6 (3’-CH), 83.6 (1’-CH), 84.6, 84.8 (4’-CH), 85.4 (Ar3C), 113.0 (CH (Ar)) 118.9, 119.0 
(CN), 122.3 (5-C), 126.6, 127.6, 127.7, 128.3, 129.6 (CH (Ar)), 135.4 (2 x C (Ar)), 137.15, 137.22 (C (Ph)), 140.5 
(8-CH), 144.8 (C (Ph)), 151.8 (4-C), 158.0 (2 x COCH3), 160.7, 160.9, 161.4 ppm (2-C, 6-C, C=N); 31P NMR 
[(CD3)2SO]:  147.8, 148.5 ppm; Mass spectrum (APCI+): m/z (Ir) 929 (M + H, 38%), 303 (100%); Calcd for 
C51H61N8O7P: (M + Na) 951.430. Found 951.429. Calcd for C51H61N8O7P: C, 66.0%; H, 6.6%; N, 12.1%; P, 3.3%. 
Found C, 65.7%; H, 6.5%; N, 12.0; P, 3.2%. 
6-Amino-2-allyloxy-6-N-[1-(dimethylamino)-ethylidene]-9-(2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-β-D-erythro-
pentofuranosyl)-purine-3'-O-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (15). The nucleoside 13 (22 mg, 
0.32 mmol) was coevaporated with anhydrous pyridine (3 x 5 mL) and suspended in anhydrous THF (4 mL) 
under Ar. To this solution was added DIPEA (0.22 mL, 1.26 mmol) followed by 2-cyanoethyl-N,N-diisopropyl 
chlorophosphoramidite (0.11 mL, 0.49 mmol). After stirring (1 h) a white precipitate had formed and the 
product mixture was concentrated and the residue purified by flash chromatography eluting with EtOAc-
CH2Cl2-Et3N (50:50:1) affording an oil which was precipitated from CH2Cl2 (3 mL) into cold hexane (300 mL). 
The product was dissolved in CH2Cl2 (3 mL) and dried under high vacuum at 30 °C giving the phosphoramidite 
15 (0.18 g, 64%) as a colourless viscous oil; mp 59-62 °C; TLC [CH2Cl2-EtOAc-Et3N (50:50:1)]: Rf 0.13; IR (cm-1): 
3411, 3056, 2968, 1606, 1568; 1H NMR [(CD3)2SO]:  0.96-1.19 (m, 12 H, 4 x CH3), 2.03 (s, 3 H, CH3), 2.63 (t, 1 H 
J 5.9 Hz, CH2CN), 2.75 (t, 1 H J 5.8 Hz, CH2CN), 2.95-3.25 (m, 8 H, (CH3)2N, 2’-CH2), 3.40-3.80 (m, 10 H, 2 x CH3O, 
POCH2, 2 x NCH, 5'-CH2), 4.1 (m, 1 H, 4’-CH), 4.62-4.80 (m, 3 H, CH2O, 3’-CH), 5.16-5.32 (m, 2 H, CH2), 5.75 (m, 1 
H, CH), 6.31 (m, 1 H, 1’-CH), 6.70-7.30 (m, 13 H, 13 x CH (Ar)), 8.13, 8.14 ppm (2 s, 1 H, 8-CH); 13C NMR 
[(CD3)2SO]:  17.1 (CH3C), 19.4 (CH2CN), 19.76 (CH2CN), 19.8 (CH2CN), 19.9 (CH2CN), 24.1, 24.18, 24.23, 24.27, 
24.29, 24.34, 24.39 (4 x CH3), 36.9, 37.0 (2’-CH2), 37.4, 38.1 ((CH3)2N), 42.5, 42.7 (2 x NCH), 54.92, 54.95, 54.96 
(2 x CH3O), 58.1, 58.3, 58.4, 58.5 (POCH2CH2CN), 63.6 (5’-CH2), 67.1 (CH2O), 72.9, 73.1, 73.3, 73.6, (3’-CH), 83.5 
(1’-CH), 84.4, 84.5, 84.7 (4’-CH), 85.5 (Ar3C), 113.0 (CH (Ar)), 116.9, 117.0 (CH2), 118.7, 119.0 (CN), 122.2, 122.3 
(5-C), 126.6, 127.6, 127.63, 129.5, 129.6, 129.64 (CH (Ar)), 133.3, 133.8, 133.81 (CH), 135.37, 135.43, 135.45 (2 
x C (Ar)), 140.2, 140.4 (8-CH), 144.8 (PhC), 151.7, 151.8 (4-C), 157.96, 157.97, 158.0 (2 x COCH3), 160.5, 160.9, 
161.3 ppm (2-C, 6-C, C=N); 31P NMR [(CD3)2SO]:  147.9, 148.6 ppm; Mass spectrum (APCI+): m/z (Ir) 879 (M + 
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